Back to Newsroom

Boston Business Journal: ACT changes name to Ocata, earns listing on the Nasdaq

Don Seiffert

Mar 4, 2015

A two decade-old biotech firm once at the center of worldwide debate over human cloning has overcome years of financial mishaps to earn a listing on the Nasdaq exchange under a new name and with a new focus on ophthalmology.

Click here to read the full article